Clinical and economic analysis of outcomes of dose tapering or withdrawal of tumor necrosis factor-α inhibitors upon achieving stable disease activity in rheumatoid arthritis patients

OBJECTIVE: To compare the real-world, 5-year clinical and cost impact of maintaining treatment with the tumor necrosis factor-α inhibitors (anti-TNFs) adalimumab, etanercept, or infliximab vs dose tapering or withdrawal in rheumatoid arthritis (RA) patients who have achieved remission (defined as a...

Descripción completa

Detalles Bibliográficos
Autores principales: Aletaha, Daniel, Snedecor, Sonya J, Ektare, Varun, Xue, Mei, Bao, Yanjun, Garg, Vishvas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546181/
https://www.ncbi.nlm.nih.gov/pubmed/28814890
http://dx.doi.org/10.2147/CEOR.S136327

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546181/
https://www.ncbi.nlm.nih.gov/pubmed/28814890
http://dx.doi.org/10.2147/CEOR.S136327

Ejemplares similares